<DOC>
	<DOCNO>NCT01651637</DOCNO>
	<brief_summary>The aim study investigate safety tolerability intratracheal administration two different single dos CHF 5633 preterm neonates RDS term adverse event , adverse drug reaction , hematology biochemistry value , incidence major neonatal morbidity include bronchopulmonary dysplasia ( BPD ) mortality .</brief_summary>
	<brief_title>First In Human Study Synthetic Surfactant CHF 5633 Respiratory Distress Syndrome</brief_title>
	<detailed_description>The study multicentre , open-label , single escalate dose , per-cohort design .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Pulmonary Surfactants</mesh_term>
	<criteria>Written inform consent obtain parents/legal representative ( accord local regulation ) prior studyrelated procedure Inborn outborn , preterm neonate either sex gestational age 27 week 33 weeks+6 Clinical radiological finding typical RDS Age admission study &lt; 24 hour birth Requirement endotracheal intubation surfactant administration Fraction inspire oxygen ( FiO2 ) &gt; 0.35 maintain SpO2 9095 % Documentation normal cranial ultrasound scan Use surfactant prior study entry need intratracheal administration treatment ( e.g . nitric oxide ) Known genetic chromosomal disorder , major congenital anomaly ( cardiac malformation , myelomeningocele etc ) Maternal drug abuse ( heroin , methadone , methamphetamine , cocaine ) significant alcohol consumption pregnancy Clinical chorioamnionitis ( Appendix III ) Strong suspicion congenital pneumonia/infection , sepsis Evidence severe birth asphyxia 5 minute Apgar score less / equal 3 Presence air leak prior study entry Neonatal seizures prior study entry Mothers prolong rupture membrane ( &gt; 3 week duration ) Any condition , opinion Investigator , would place neonate undue risk Participation another clinical trial placebo , drug biological substance conduct provision protocol</criteria>
	<gender>All</gender>
	<minimum_age>27 Weeks</minimum_age>
	<maximum_age>34 Weeks</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Respiratory Distress syndrome</keyword>
	<keyword>Complications prematurity</keyword>
</DOC>